FDA Approves Ziihera for HER2-Positive Biliary Tract Cancer

ZYME Stock  USD 11.31  0.01  0.09%   
About 65% of Zymeworks Common's investor base is looking to short. The analysis of the overall investor sentiment regarding Zymeworks Common Stock suggests that many traders are alarmed. The current market sentiment, together with Zymeworks Common's historical and current headlines, can help investors time the market. In addition, many technical investors use Zymeworks Common Stock stock news signals to limit their universe of possible portfolio assets.
The U.S. Food and Drug Administration approved Ziihera , developed by Zymeworks , for the treatment of adults with previousl

Read at gurufocus.com
Gurufocus Stories at Macroaxis
  

Zymeworks Common Stock Current Investor Sentiment

Comfort Level 35

 Alarmed

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Zymeworks Common's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Zymeworks Common Stock.

Zymeworks Common Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Zymeworks Common can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Zymeworks Common Stock Historical Investor Sentiment

Investor biases related to Zymeworks Common's public news can be used to forecast risks associated with an investment in Zymeworks. The trend in average sentiment can be used to explain how an investor holding Zymeworks can time the market purely based on public headlines and social activities around Zymeworks Common Stock. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Zymeworks Common's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Zymeworks Common and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Zymeworks Common news discussions. The higher the estimate score, the more favorable the investor's outlook on Zymeworks Common.

Zymeworks Common Fundamental Analysis

We analyze Zymeworks Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zymeworks Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zymeworks Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Zymeworks Common is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Zymeworks Common Stock Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Zymeworks Common stock to make a market-neutral strategy. Peer analysis of Zymeworks Common could also be used in its relative valuation, which is a method of valuing Zymeworks Common by comparing valuation metrics with similar companies.

Peers

Zymeworks Common Related Equities

ALECAlector   12.50   
0%
100.0%
EDITEditas Medicine   4.32   
0%
34.0%
PRQRProQR Therapeutics   3.87   
0%
30.0%
STOKStoke Therapeutics   3.43   
0%
27.0%
RLAYRelay Therapeutics   1.69   
0%
13.0%
TERNTerns Pharmaceuticals   1.33   
0%
10.0%
BPMCBlueprint Medicines   1.61   
12.0%
0%
CABACabaletta Bio   1.65   
13.0%
0%
ARWRArrowhead Pharmaceuticals   1.66   
13.0%
0%
TVTXTravere Therapeutics   2.05   
16.0%
0%
PTGXProtagonist Therapeutics   2.16   
17.0%
0%
ZNTLZentalis Pharmaceuticals   2.38   
19.0%
0%
CYTKCytokinetics   2.40   
19.0%
0%
SNDXSyndax Pharmaceuticals   2.82   
22.0%
0%
APLSApellis Pharmaceuticals   2.86   
22.0%
0%
RVMDRevolution Medicines   3.56   
28.0%
0%
YMABY MAbs   3.71   
29.0%
0%
DAWNDay One   4.59   
36.0%
0%
BLUEBluebird Bio   5.66   
45.0%
0%
ANNXAnnexon   5.88   
47.0%
0%
MRSNMersana Therapeutics   5.88   
47.0%
0%
AKROAkero Therapeutics   5.99   
47.0%
0%
INZYInozyme Pharma   7.26   
58.0%
0%

Complementary Tools for Zymeworks Stock analysis

When running Zymeworks Common's price analysis, check to measure Zymeworks Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zymeworks Common is operating at the current time. Most of Zymeworks Common's value examination focuses on studying past and present price action to predict the probability of Zymeworks Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zymeworks Common's price. Additionally, you may evaluate how the addition of Zymeworks Common to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance